ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Mark Kris on Immunotherapy and Frontline Options for Patients With NSCLC

Mark G. Kris, MD
Published: Friday, Jun 17, 2016


Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, explains what community oncologists need to know regarding immunotherapy and frontline treatment options for patients with non–small cell lung cancer (NSCLC).

During the Cleveland Clinic/OncLive 2016 State of the Science Summit on Lung Cancer, Kris explains how the quantity of therapies available for patients have significantly increased over the past decade. The landscape has evolved, he adds, with the development of immunotherapy and targeted therapies.

Going forward, community oncologists need to determine how to best choose amongst the available therapies for their individual patients. They can do this by utilizing the resources they may have at their disposal, Kris says. 

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, explains what community oncologists need to know regarding immunotherapy and frontline treatment options for patients with non–small cell lung cancer (NSCLC).

During the Cleveland Clinic/OncLive 2016 State of the Science Summit on Lung Cancer, Kris explains how the quantity of therapies available for patients have significantly increased over the past decade. The landscape has evolved, he adds, with the development of immunotherapy and targeted therapies.

Going forward, community oncologists need to determine how to best choose amongst the available therapies for their individual patients. They can do this by utilizing the resources they may have at their disposal, Kris says. 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x